A pilot randomized trial to prevent sexual dysfunction in postmenopausal breast cancer survivors starting adjuvant aromatase inhibitor therapy

2017 ◽  
Vol 11 (4) ◽  
pp. 477-485 ◽  
Author(s):  
Pragati Advani ◽  
Abenaa M. Brewster ◽  
George P. Baum ◽  
Leslie R. Schover
Keyword(s):  
Breast Cancer ◽  
Sexual Dysfunction ◽  
Cancer Survivors ◽  
Randomized Trial ◽  
Aromatase Inhibitor ◽  
Breast Cancer Survivors ◽  
Postmenopausal Breast Cancer ◽  
Inhibitor Therapy ◽  
Aromatase Inhibitor Therapy

scholarly journals The Relationship Between Insomnia and Cognitive Impairment in Breast Cancer Survivors

2019 ◽  
Vol 3 (3) ◽  
Author(s):  
Kevin T Liou ◽  
Tim A Ahles ◽  
Sheila N Garland ◽  
Q Susan Li ◽  
Ting Bao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cognitive Impairment ◽  
Cancer Survivors ◽  
Aromatase Inhibitor ◽  
Breast Cancer Survivors ◽  
Postmenopausal Breast Cancer ◽  
Inhibitor Therapy ◽  
Cancer Center ◽  
Aromatase Inhibitor Therapy ◽  
Insomnia Severity

Abstract Background Cancer-related cognitive impairment is an emerging public health burden. Growing research suggests that sleep disturbances contribute to poor cognition. Our study aimed to evaluate the association between insomnia and cognitive impairment in breast cancer survivors. Methods We analyzed cross-sectional data from a cohort study of postmenopausal women with stage 0–III hormone receptor-positive breast cancer on aromatase inhibitor therapy. The study was conducted between November 2011 and April 2015 at an academic cancer center (Philadelphia, PA). Insomnia was assessed with the Insomnia Severity Index. Perceived cognitive impairment was assessed with the cognitive subscale of the Breast Cancer Prevention Trial Symptom Checklist. We used linear regression to evaluate the association between insomnia and perceived cognitive impairment. Results Among 1072 patients, 556 (51.9%) reported insomnia and 847 (79.0%) were bothered by cognitive symptoms (forgetfulness, difficulty concentrating, distractibility). Greater perceived cognitive impairment was reported by patients with mild insomnia (regression coefficient [β] = 0.35, 95% confidence interval [CI] = 0.23 to 0.46, P < .001), moderate insomnia (β = 0.51, 95% CI = 0.36 to 0.65, P < .001), and severe insomnia (β = 0.94, 95% CI = 0.67 to 1.21, P < .001), compared with those without insomnia. Greater perceived cognitive impairment was also associated with patients younger than 55 years (β = 0.30, 95% CI = 0.15 to 0.45, P < .001), taxane-based chemotherapy (β = 0.11, 95% CI = 0.004 to 0.22, P = .04), anxiety (β = 0.47, 95% CI = 0.30 to 0.64, P < .001), and depression (β = 0.65, 95% CI = 0.35 to 0.94, P < .001). Conclusions Among postmenopausal breast cancer survivors receiving aromatase inhibitor therapy, insomnia and cognitive impairment are prevalent and characterized by a graded association, in which severity of perceived cognitive impairment increases as insomnia severity increases. Our findings warrant further research to determine whether addressing sleep is a strategy to improve management of cancer-related cognitive impairment.

scholarly journals Effects of resistance plus aerobic training on body composition and metabolic markers in older breast cancer survivors undergoing aromatase inhibitor therapy

2018 ◽  
Vol 111 ◽  
pp. 210-217 ◽  
Author(s):  
Thais R.S. de Paulo ◽  
Kerri M. Winters-Stone ◽  
Juliana Viezel ◽  
Fabricio E. Rossi ◽  
Regina R. Simões ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Composition ◽  
Cancer Survivors ◽  
Aromatase Inhibitor ◽  
Breast Cancer Survivors ◽  
Aerobic Training ◽  
Inhibitor Therapy ◽  
Metabolic Markers ◽  
Aromatase Inhibitor Therapy

Aromatase inhibitor therapy and hair loss among breast cancer survivors

2013 ◽  
Vol 142 (2) ◽  
pp. 435-443 ◽  
Author(s):  
Lisa Gallicchio ◽  
Carla Calhoun ◽  
Kathy J. Helzlsouer
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Aromatase Inhibitor ◽  
Hair Loss ◽  
Breast Cancer Survivors ◽  
Inhibitor Therapy ◽  
Aromatase Inhibitor Therapy

Joint pain and physical activity among breast cancer survivors on aromatase inhibitor therapy.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e11564-e11564
Author(s):  
Kirsten A Nyrop ◽  
Hyman Muss ◽  
Betsy Hackney ◽  
Rebecca Clevalend ◽  
Leigh F. Callahan
Keyword(s):  
Breast Cancer ◽  
Physical Activity ◽  
Cancer Survivors ◽  
Aromatase Inhibitor ◽  
Joint Pain ◽  
Breast Cancer Survivors ◽  
Inhibitor Therapy ◽  
Aromatase Inhibitor Therapy
Sign in / Sign up

Export Citation Format

Share Document